0001171843-22-004591.txt : 20220629 0001171843-22-004591.hdr.sgml : 20220629 20220629080209 ACCESSION NUMBER: 0001171843-22-004591 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220629 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220629 DATE AS OF CHANGE: 20220629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 221051823 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 f8k_062922.htm FORM 8-K Form 8-K
0001629137 False 0001629137 2022-06-29 2022-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 29, 2022

_______________________________

Global Blood Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3753927-4825712
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

181 Oyster Point Blvd.

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 741-7700

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareGBTThe NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

In this report, "GBT," "Company," "we," "our," and "us" means Global Blood Therapeutics, Inc., and/or one or more of our subsidiaries, unless the context otherwise provides.

Item 8.01. Other Events.

On June 29, 2022, Global Blood Therapeutics, Inc. issued a press release titled "GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description
   
99.1 Press Release, dated June 29, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Global Blood Therapeutics, Inc.
   
  
Date: June 29, 2022By: /s/ Jeffrey Farrow        
  Jeffrey Farrow
  Chief Financial Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trial

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601 (GBT601), the company’s investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor. The study (NCT05431088) is a randomized, multicenter Phase 2/3 clinical trial evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of GBT601.

“Based on compelling preclinical and clinical data, we believe GBT601 has the potential to be a best-in-class therapy for patients with sickle cell disease,” said Kim Smith-Whitley, M.D., executive vice president and head of research and development of GBT. “Specifically, it has the potential to improve on the clinical results achieved with Oxbryta® at a lower daily dose. The initiation of our Phase 2/3 trial is an important milestone in our efforts to bring GBT601 to patients. We anticipate that initial data from this trial as well as data from the continuation of our GBT601 Phase 1 study will be available before the end of the year.”

The study is planned to include sites in Africa, Europe, the Middle East, South America, and the United States, including several sites that are expected to begin enrolling patients in the near term. The Phase 2 portion of the study will evaluate the safety, tolerability, and efficacy of GBT601 and enroll up to 60 patients with SCD who are 18 to 65 years of age. Patients with hemoglobin (Hb) levels between 5.5 g/dL and 10.5 g/dL and 10 or fewer vaso-occlusive crises in the prior year are eligible for enrollment. Patients will be randomized 1:1:1 to a daily maintenance dose of GBT601 of 100, 150 or up to 200 mg. The primary outcome measure is the number of participants with a change from baseline in Hb through Week 12. Secondary outcomes measures include assessments of PK and PD, as well as an assessment of the relationship between GBT601 and measures of anemia and hemolysis.

Following the selection of the optimal safe and effective dose of GBT601 from the Phase 2 portion of the study, the Phase 3 portion will assess the efficacy and safety of the selected optimal dose compared to placebo in adult and pediatric SCD patients for 48 weeks. In addition, a third arm of the study will evaluate the PK and safety of single and multiple doses of GBT601 in an open-label single arm study with pediatric participants.

About Sickle Cell Disease
Sickle cell disease (SCD) affects more than 100,000 people in the United States,1 an estimated 52,000 people in Europe,2 up to 100,000 people in Brazil,3 and millions of people throughout the world, particularly among those whose ancestors are from sub-Saharan Africa.4 It also affects people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.5 SCD is a lifelong, devastating inherited blood disorder that impacts hemoglobin, a protein carried by red blood cells that delivers oxygen to tissues and organs throughout the body.5 Due to a genetic mutation, individuals with SCD form abnormal hemoglobin known as sickle hemoglobin. When sickle hemoglobin becomes deoxygenated, it polymerizes to form rods, which deforms the red blood cells into sickled – crescent-shaped, rigid – cells. 3,5,6 The recurrent sickling process causes destruction of the red blood cells, hemolysis and anemia (low hemoglobin due to red blood cell destruction) which drives vascular inflammation contributing to blockages in capillaries and small blood vessels (vaso-occlusion) that impede the flow of blood and oxygen delivery throughout the body. Episodes of painful vascular occlusions are commonly referred to as vaso-occlusive crises (VOCs). The diminished oxygen delivery to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage. 3,6,7,8 Complications of SCD can begin in early childhood and can include neurocognitive impairment, acute chest syndrome, and silent and overt stroke, among other serious issues.9 Early intervention and treatment of SCD have shown potential to modify the course of this disease, reduce symptoms and events, prevent long-term organ damage, and extend life expectancy.10

About GBT601
Discovered and designed by GBT’s research and development team, GBT021601 (GBT601) has the same mechanism of action as Oxbryta (voxelotor), with the potential for improved clinical results by achieving higher hemoglobin levels and occupancy at a lower dose. GBT601 is being studied in a Phase 1 clinical trial and Phase 2 portion of a Phase 2/3 clinical trial.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “will,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects” and “intends,” or similar expressions. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GBT intends these forward-looking statements, including statements regarding GBT’s priorities, dedication, commitment, focus, goals, mission, vision and positioning; safety, efficacy and mechanism of action of Oxbryta and other product characteristics; commercialization, delivery, availability, use and commercial and medical potential of Oxbryta; significance of the initiation of the Phase 2/3 trial of GBT601 and bringing GBT601 to patients; clinical trials of GBT601 and other ongoing and planned studies, clinical trials and registries, including related protocols, enrollment and other activities, timing, data availability and other expectations; significance of preclinical and clinical data of GBT601, including with respect to the potential of GBT601; safety, efficacy, mechanism of action, advancement and potential of GBT601, inclacumab and GBT’s other drug candidates and its pipeline; impacting the treatment, course and care of SCD; and working on new targets and discovering, developing and delivering treatments, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and GBT makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect GBT’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. GBT can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond GBT’s control, including, without limitation, risks and uncertainties relating to the COVID-19 pandemic, including the extent and duration of the impact on GBT’s business, including commercialization activities, regulatory efforts, research and development, corporate development activities and operating results, which will depend on future developments that are highly uncertain and cannot be accurately predicted, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease; the risks that GBT is continuing to establish its commercialization capabilities and may not be able to successfully commercialize Oxbryta; risks associated with GBT’s dependence on third parties for research, development, manufacture, distribution and commercialization activities; government and third-party payer actions, including those relating to reimbursement and pricing; risks and uncertainties relating to competitive treatments and other changes that may limit demand for Oxbryta; the risks regulatory authorities may require additional studies or data to support continued commercialization of Oxbryta; the risks that drug-related adverse events may be observed during commercialization or clinical development; data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval; compliance with obligations under the Pharmakon loan; and the timing and progress of activities under GBT’s collaboration, license and distribution agreements; along with those risks set forth in GBT’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and in GBT’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in GBT’s subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, GBT assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

References

  1. Centers for Disease Control and Prevention website. Sickle Cell Disease Research. https://www.cdc.gov/ncbddd/hemoglobinopathies/scdc-understanding-sickle-cell-disease.html. Accessed February 23, 2022.
  2. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125 Accessed February 23, 2022.
  3. Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
  4. Centers for Disease Control and Prevention website. Sickle Cell Disease (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed February 23, 2022.
  5. National Heart, Lung, and Blood Institute website. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed February 23, 2022.
  6. Rees DC, et al. Lancet. 2010;376(9757):2018-2031.
  7. Kato GJ, et al. J Clin Invest. 2017;127(3):750-760.
  8. Caboot JB, et al. Paediatr Respir Rev. 2014;15(1):17-23.
  9. Kanter J, et al. Blood Rev. 2013 Nov;27(6):279-87.
  10. Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.

Contact:
Steven Immergut (media)
+1 650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
+1 650-351-7881
croberts@gbt.com

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jun. 29, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 29, 2022
Entity File Number 001-37539
Entity Registrant Name Global Blood Therapeutics, Inc.
Entity Central Index Key 0001629137
Entity Tax Identification Number 27-4825712
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 181 Oyster Point Blvd.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 741-7700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_062922_htm.xml IDEA: XBRL DOCUMENT 0001629137 2022-06-29 2022-06-29 iso4217:USD shares iso4217:USD shares 0001629137 false 8-K 2022-06-29 Global Blood Therapeutics, Inc. DE 001-37539 27-4825712 181 Oyster Point Blvd. South San Francisco CA 94080 650 741-7700 false false false false Common Stock, par value $0.001 per share GBT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_062922.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_062922.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_062922.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_062922.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_062922.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-004591-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-004591-xbrl.zip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end